Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

BioSpecifics Technologies Corp. to Host Conference Call to Report Fourth Quarter and Full Year 2012 Financial Results on



   BioSpecifics Technologies Corp. to Host Conference Call to Report Fourth
   Quarter and Full Year 2012 Financial Results on Tuesday, March 12, 2013

PR Newswire

LYNBROOK, N.Y., March 5, 2013

LYNBROOK, N.Y., March 5, 2013 /PRNewswire/ -- BioSpecifics Technologies Corp.
(NASDAQ: BSTC), a biopharmaceutical company developing first in class
collagenase-based products marketed as XIAFLEX^® in the U.S., announced today
that it will host a conference call and live audio webcast at 4:30 p.m. EDT on
Tuesday, March 12, 2013 to report its fourth quarter and full year 2012
financial results and provide a corporate update.

In order to participate in the conference call, please dial 1-800-860-2442
(domestic) or 1-412-858-4600 (international). The live webcast can be accessed
under "Calendar of Events" in the Investor Relations section of the Company's
website at www.biospecifics.com or you may use the link:
http://www.videonewswire.com/event.asp?id=92436.

A replay of the call will be available one hour after the end of the
conference on March 12, 2013 until 9:00 a.m. EDT on March 27, 2013. To access
the replay, please dial 1-877-344-7529 (domestic) or 1-412-317-0088
(international) and reference the access code 10025434. The archived webcast
will be available for 90 days in the Investor Relations section of
BioSpecifics' website at www.biospecifics.com.

About BioSpecifics Technologies Corp.
BioSpecifics Technologies Corp. is a biopharmaceutical company that has
developed injectable collagenase for twelve clinical indications. Injectable
collagenase is currently marketed as XIAFLEX^® in the U.S. for the treatment
of adult Dupuytren's contracture patients with a palpable cord by Auxilium
Pharmaceuticals, Inc. (Auxilium) and is approved for Dupuytren's contracture
in the European Union, Switzerland and Canada. XIAFLEX is also in clinical
development for the treatment of several additional promising indications. A
supplemental Biologics License Application is currently under standard review
at the U.S. Food and Drug Administration for XIAFLEX for the potential
treatment of Peyronie's disease. Auxilium is also testing XIAFLEX for frozen
shoulder syndrome (adhesive capsulitis) and cellulite in Phase IIa and Phase
Ib clinical trials, respectively. BioSpecifics is currently managing the
clinical development of XIAFLEX for the treatment of human lipoma and canine
lipoma, which are both in Phase II clinical trials. Auxilium is currently
partnered with Asahi Kasei Pharma Corporation for the development and
commercialization of injectable collagenase for Dupuytren's contracture and
Peyronie's disease in Japan and with Actelion Pharmaceuticals Ltd. for these
same indications in Canada, Australia, Brazil and Mexico. Pfizer Inc. has
marketing rights to XIAPEX^® (the EU trade name for XIAFLEX) for Dupuytren's
contracture in 46 countries in Eurasia through April 24, 2013.  For more
information, please visit www.biospecifics.com.

SOURCE BioSpecifics Technologies Corp.

Website: http://www.biospecifics.com
Contact: Thomas L. Wegman, President, BioSpecifics Technologies Corp.,
+1-516-593-7000, thomas_wegman@biospecifics.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement